Glaucoma - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Glaucoma - Pipeline Review, H2 2013 market report to its offering
Glaucoma - Pipeline Review, H2 2013


, 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Glaucoma - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Glaucoma.
- A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Glaucoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Alcon, Inc.
F. Hoffmann-La Roche Ltd.
Bausch & Lomb Incorporated
Allergan, Inc.
QLT Inc.
Advanced Cell Technology, Inc.
Quark Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Oxford BioMedica plc
RetinaPharma Technologies, Inc.
Novagali Pharma SA
Kowa Company, Ltd.
Merz GmbH & Co. KGaA
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Sun Pharmaceutical Industries Limited
InSite Vision Incorporated
Can-Fite BioPharma Ltd.
NicOx SA
ACADIA Pharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc.
NeoStem, Inc.
Summit Corporation plc
Cancer Research Technology Limited
Ceregene, Inc.
AC Immune SA
Colby Pharmaceutical Company
Upsher-Smith Laboratories, Inc.
Foamix Ltd.
Senju Pharmaceutical Co., Ltd.
Neurotech Pharmaceuticals, Inc.
Gene Signal International SA.
Asahi Kasei Pharma
Inotek Pharmaceuticals Corporation
CeNeRx BioPharma, Inc.
Intellect Neurosciences, Inc.
PharmaNova Inc.
Aerie Pharmaceuticals, Inc.
Lacer, S.A.
Altacor Ltd.
Ascenion GmbH
Inserm Transfert SA
Mimetogen Pharmaceuticals Inc.
Icon Bioscience, Inc.

To view the table of contents for this market research report please visit